About
Xbrane Biopharma AB is a biopharmaceutical company, which engages in the development and manufacture of biosimilars. The company is headquartered in Solna, Stockholm and currently employs 92 full-time employees. The company went IPO on 2016-02-03. The company develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The firm's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Annual results
Reported figures, SEK · revenue down 23.2% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 152M | 127M | 83.6% | — |
| 2024 | 198M | -266M | -134.3% | — |
| 2023 | 238M | -388M | -163.0% | — |
| 2022 | 57.0M | -172M | -301.8% | — |
| 2021 | 11.0M | -191M | -1736.4% | — |
XBRANE.ST in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Xbrane Biopharma AB are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.